Trial Profile
On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ROLL
- 24 Apr 2015 New trial record